Publication:
S244. CHARACTERIZING OUTCOMES OF CLINICAL HIGH-RISK NON-CONVERTERS USING GROUP-BASED TRAJECTORY MODELING

Thumbnail Image

Date

2018

Journal Title

Journal ISSN

Volume Title

Publisher

Oxford University Press
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Allswede, D., T. Cannon, J. Addington, C. Bearden, K. Cadenhead, B. Cornblatt, D. Mathalon, et al. 2018. “S244. CHARACTERIZING OUTCOMES OF CLINICAL HIGH-RISK NON-CONVERTERS USING GROUP-BASED TRAJECTORY MODELING.” Schizophrenia Bulletin 44 (Suppl 1): S422. doi:10.1093/schbul/sby018.1031. http://dx.doi.org/10.1093/schbul/sby018.1031.

Research Data

Abstract

Abstract Background: The development of the clinical high-risk (CHR) prodromal criteria has facilitated advancement in understanding conversion to psychosis and has provided opportunities for early intervention and treatment for these individuals. However, the majority of CHR cases do not meet full criteria for conversion, yet continue to experience clinically significant symptoms and impairment in daily functioning. It is likely that many of these individuals would also benefit from additional intervention and treatment, but the outcomes and needs of these “non-converters” are not well characterized. Identifying common longitudinal patterns of symptoms and functioning of non-converters would support the identification of individuals who continue to require treatment and tailoring of services to their specific needs. Methods: We used group-based trajectory modeling to identify common longitudinal symptom and functioning trajectories among CHR cases (N=561) in the second phase of the North American Prodrome Longitudinal Study (NAPLS2). Covariant trajectories of symptoms (including positive, negative, disorganized, and general) and functioning (including role and social) were examined. Models were tested for replicability in an independent sample of CHR cases (N=291) from the first phase of NAPLS (NAPLS1). Results: We identified a subgroup of individuals who exhibited symptom remission and functioning within the normal range, as well as at least two additional subgroups that exhibited different patterns of ongoing, clinically significant symptoms and functional deficits. Discussion We are currently investigating the validity of these subgroups by assessing their association with a variety of risk factors and biomarkers.

Description

Keywords

Poster Session III

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Referenced By

Related Stories